Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson’s disease

Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson’s disease

Both continuous oxidative stress and poly (ADP-ribose) polymerase 1 (PARP-1) activation occur in neurodegenerative diseases such as Parkinson’s disease. PARP-1 inhibition can reverse mitochondrial damage and has a neuroprotective effect. In a previous study, we synthesized melatonin derivative 6a (M...

Full description

Bibliographic Details
Main Authors: Qing-Wei Ma, Rui-Ting Han, Zi-Jie Wu, Jun-Jie Zhou, Meng-Ting Chen, Xiang-Zhi Zhang, Wen-Zhe Ma, Na Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Pharmacology
Subjects:
melatonin derivative
Parkinson’s disease
PARP-1
mTOR
mitochondrial dysfunction
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1363212/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1363212/full

Similar Items